CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity

Immunotherapies have heralded a new era in the cancer treatment. In addition to checkpoint inhibitors, agonistic antibodies against co-stimulatory immune receptors hold the potential to invoke efficient antitumor immunity. Targeting CD137 has gained momentum based on its ability to drive NK- and T-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Stoll, A., Bruns, H., Fuchs, M., Völkl, S., Nimmerjahn, F., Kunz, M., Peipp, M., Mackensen, A., Mougiakakos, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632678/
https://www.ncbi.nlm.nih.gov/pubmed/34021248
http://dx.doi.org/10.1038/s41375-021-01287-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632678/
https://www.ncbi.nlm.nih.gov/pubmed/34021248
http://dx.doi.org/10.1038/s41375-021-01287-1

Ejemplares similares